South Korea Liquid Biopsy Market Size, Share, and COVID-19 Impact Analysis, By Type (Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles, and Others), By Application (Cancer Therapeutic Application, Reproductive Health, and Others), and South Korea Liquid Biopsy Market Insights, Industry Trend, Forecasts to 2035

South Korea Liquid Biopsy Market Insights Forecasts to 2035

• The South Korea Liquid Biopsy Market Size was Estimated at USD 192.0 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 10.33% from 2025 to 2035
• The South Korea Liquid Biopsy Market Size is Expected to Reach USD 566.0 Million by 2035

According to a research report published by Spherical Insights & Consulting, The South Korea Liquid Biopsy Market Size is anticipated to reach USD 566.0 Million by 2035, growing at a CAGR of 10.33% from 2025 to 2035. Driven by the high rate of cancer, the growing need for non-invasive diagnostic techniques, and the robust government backing of R&D and precision medicine programs. Innovation and adoption are being further accelerated by technological developments in biomarker detection and expanding partnerships between biotech companies and academic institutions.

Market Overview

The South Korean liquid biopsy market is the area of the nation's medical and diagnostics sector devoted to non-invasive testing techniques that examine biomarkers from bodily fluids like blood or urine, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles. These tests provide a less invasive option to conventional tissue biopsies and are mainly utilized for early cancer detection, treatment monitoring, and customized therapy guidance. Additionally, the South Korean government is actively promoting research and development in this area, which motivates regional businesses to improve their capacities and produce competitive goods. The increasing cooperation between academic institutions and biotechnology firms with the goal of quickening the development of liquid biopsy applications is another trend. Since South Korea is renowned for its robust research capabilities and educational institutions, which support a constant flow of innovation, this partnership is essential. Investing in liquid biopsy technologies is being driven by the rising incidence of cancer in the nation, which highlights the need for effective diagnostic tools. Moreover, there are also a lot of opportunities to combine the results of liquid biopsies with information from other sources, like genomics and patient medical records, to provide more thorough insights.

Report Coverage

This research report categorizes the market for the South Korea liquid biopsy market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea liquid biopsy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea liquid biopsy market.

Driving Factors

One of the main factors propelling the South Korean liquid biopsy market industry is the country's rising cancer incidence rate. According to the South Korean National Cancer Center, the number of cancer cases has dramatically increased, with an estimated 240,000 new cases reported each year. This rate indicates a strong need for novel diagnostic approaches because conventional biopsy techniques are inconvenient and require invasive procedures. A liquid biopsy, on the other hand, provides a faster, less invasive way to evaluate and track tumor dynamics. The Society of Medical Oncology is promoting the integration of liquid biopsy technologies to enhance patient outcomes and is pushing for research and development in this field. Given a strong population base and rising rates of cancer diagnoses, South Korea's liquid biopsy market is expected to grow significantly over the next several years.

Restraining Factors

High testing costs, restrictive reimbursement guidelines, and technical difficulties with biomarker standardization are the main obstacles facing the South Korean liquid biopsy market. Furthermore, despite the growing demand for non-invasive diagnostics, widespread adoption is slowed down by regulatory barriers for clinical validation and general practitioners' lack of awareness.

Market Segmentation

The South Korea liquid biopsy market share is classified into type and application.

• The circulating tumor cells segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea liquid biopsy market is segmented by type into circulating tumor cells, circulating tumor DNA, extracellular vesicles, and others. Among these, the circulating tumor cells segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The high sensitivity of ctDNA in identifying genetic mutations, its efficiency in tracking the development of tumors, and its expanding application in individualized cancer treatment plans are the reasons for this dominance. Its broad clinical adoption is further supported by the fact that it is non-invasive.

• The cancer therapeutic application segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea liquid biopsy market is segmented by application into cancer therapeutic application, reproductive health, and others. Among these, the cancer therapeutic application segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Since it provides non-invasive ways to track tumor growth and treatment response, the cancer therapeutic application is especially important for individualized cancer care. This aligns with the South Korean government's efforts to promote cutting-edge medical technology, which will lead to better patient outcomes.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea liquid biopsy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• EONE-Diagnomics Genome Center
• Macrogen Inc.
• Seegene Inc.
• Geninus Inc.
• BioSewoom Inc.
• Others

Recent Developments:

• In September 2021, A South Korean startup partnered with Germany’s Molecular Health GmbH and launched ONCOCATCH-CDx, a non-invasive liquid biopsy platform. This collaboration aimed to strengthen South Korea’s position in the precision medicine market by offering early cancer detection and personalized treatment guidance.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea Liquid Biopsy Market based on the below-mentioned segments:

South Korea Liquid Biopsy Market, By Types

• Circulating Tumor Cells
• Circulating Tumor DNA
• Extracellular Vesicles
• Others

South Korea Liquid Biopsy Market, By Application

• Cancer Therapeutic Application
• Reproductive Health
• Others